It is exactly considerations like this that make the DNDN disregard for science more puzzling. Their IT infrastructure, in vitro approach, and need to monitor contamination, LPS is a good case in point, give them the ideal platform from which to sort out these inconsistent results. So, why the interest in video and politics? A few IT guys playing with their clinical monitoring data could probably do quite a bit. Again, there is some hope their new CFO is leading an array based science effort but I won't make any assumptions until I see some evidence ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.